Recommend to a friend

Considering Biosimilars in Patients Failing their Initial Biologic

Upon completion of the activity, participants should be able to explain the circumstances under which it is appropriate to initiate or switch a patient with a rheumatologic disease to a biosimilar.
IL-rheum-case3